Sai Life Sciences Ltd. sees a credit rating action
TL;DR
According to the India Ratings rationale, what specific improvements in the company's financial risk profile—such as debt-to-EBITDA ratios or free cash flow generation—were the primary catalysts for the upgrade to IND AA, and how do these metrics compare to the company's historical performance over the last three fiscal years?
The key distinction is that the detailed India Ratings rationale available here relates to the upgrade to IND AA- from IND A+ in August 2025, not the later move to IND AA from IND AA-. The later announcement records the rating action but does not provide the supporting debt-to-EBITDA or free-cash-flow thresholds. [1] [2]
What drove the documented upgrade
The quantified improvements in the detailed rationale were:
- Stronger operating performance in FY25, which India Ratings identified as the principal basis for the upgrade. [1]
- Higher operating cash generation: cash flow from operations rose to ₹314.0 Cr in FY25 from ₹263.1 Cr in FY24, an increase of approximately 19.3%, attributed to favourable working-capital changes. [1]
- Stronger liquidity: cash balances including unencumbered fixed deposits increased to ₹372.3 Cr at FY25-end from ₹184.7 Cr at FY24-end, roughly doubling. The rating rationale also cited no debt repayment obligations. [1]
A specific debt-to-EBITDA target or reported FCF figure was not included in the cited rationale, so it cannot be confirmed that either metric was the primary trigger for the rating action. The reported cash-flow improvement was CFO, not free cash flow.
Comparison with the last three fiscal years
† Derived as FY26 year-end total debt of ₹95.12 Cr divided by FY26 EBITDA of ₹680.30 Cr. [4] [6]
The cleanest historical evidence therefore supports deleveraging and better operating cash generation between FY24 and FY25/FY26, rather than a demonstrable three-year improvement in FCF. A third-party assessment described FCF as negative in three of the preceding five years, with cumulative FCF of approximately negative ₹10 Cr, but it did not provide FY24-FY26 annual figures. [7]
One important qualification is that total debt had risen to ₹448.25 Cr by Q2 FY27, so the FY26 0.14x ratio should be treated as a historical year-end measure, not as the company’s latest leverage position. [8]
| Metric | FY24 | FY25 | FY26 | Interpretation |
|---|---|---|---|---|
| Total debt at year-end (₹ Cr) | Could not be confirmed | 128.64 [3] | 95.12 [4] | FY26 debt declined 26.1% YoY [5] |
| EBITDA (₹ Cr) | Could not be confirmed | Could not be confirmed | 680.30 [6] | FY26 is the only year with a reported full-year EBITDA figure |
| Debt / EBITDA | Could not be confirmed | Could not be confirmed | 0.14x, derived† | Indicates low FY26 year-end leverage, but a three-year trend cannot be established |
| Cash flow from operations (₹ Cr) | 263.1 [1] | 314.0 [1] | Could not be confirmed | Clear FY25 improvement, driven by working capital |
| Free cash flow | Could not be confirmed | Could not be confirmed | Could not be confirmed | No FY24-FY26 annual FCF series is available in the cited material |
Following the upgrade to IND AA, what is the management's guidance on the expected reduction in the weighted average cost of debt, and how does this align with the company's current interest coverage ratio as disclosed in the latest annual report?
Management’s guidance on the expected reduction in weighted average cost of debt could not be confirmed from the cited materials. The IND AA upgrade was announced by India Ratings on 13 November 2026, but the disclosure does not quantify any reduction in borrowing cost or provide a new target WACD. It covers bank-loan facilities of ₹769 Cr and moves the long-term rating from IND AA- to IND AA, with the short-term rating affirmed at IND A1+ [9].
Interest coverage remains strong: the FY26 consolidated interest coverage ratio is reported at 12.88x [10]. A separate rating-analysis definition reports FY26 gross interest coverage of 16.1x, calculated using EBITDA and gross interest expense [11]. These figures should not be treated as contradictory without reconciling the calculation definitions.
The implication is that Sai Life Sciences already has substantial interest-servicing headroom, so any reduction in WACD would be a positive incremental benefit rather than necessary to support current debt service. However, the rating agency expects credit metrics to moderate as the company funds its FY27 capex programme through internal accruals and incremental borrowings [11]. Therefore, the upgrade supports the possibility of cheaper refinancing, but the evidence does not establish a quantified saving or confirm that it has already flowed through to the company’s interest cost.
How does Sai Life Sciences' current leverage profile (Net Debt/EBITDA) post-upgrade compare to other mid-cap CDMO peers in the Indian market, and does this rating action reflect a structural shift in the company's capital allocation strategy regarding future capex funding?
Verdict: Sai Life Sciences is currently at the high-leverage end of the comparison set on the latest Q2 FY27 balance-sheet snapshot: its reported Net Debt/EBITDA was 2.19x, close to Emcure’s 2.25x. On a TTM basis, however, Sai’s 0.57x is slightly below Emcure’s 0.63x, but materially above Ipca and Ajanta; Glaxo and Acutaas were in net-cash positions. [12] [13] The upgrade reflects improved profitability and credit quality, not evidence of a permanent move to debt-led capex funding.
Leverage comparison
All figures are consolidated and aligned to Q2 FY27; the Q2 ratio is a point-in-time net-debt measure against that quarter’s EBITDA, while TTM is the more stable comparison.
The important distinction is between current funding intensity and underlying earning capacity:
- Sai’s Q2 ratio of 2.19x is elevated relative to Ajanta, Ipca, Glaxo and Acutaas, and is broadly comparable with Emcure.
- On TTM EBITDA, Sai at 0.57x remains below Emcure at 0.63x, indicating that the current leverage increase has not yet translated into high annualised leverage.
- Sai is not directly comparable with every company as a pure CDMO peer. The rating analysis identifies Sai as a CRO/CDMO, with CDMO contributing 65% of FY26 revenue; equivalent CDMO exposure is not established for each comparator in the cited material. [11]
What the rating upgrade actually says
India Ratings upgraded Sai’s long-term bank-loan rating from IND AA-/Positive to IND AA/Stable on 13 November 2026, while affirming the short-term rating at IND A1+. [9] The upgrade was based on the improvement in operating performance and credit metrics: adjusted net leverage was 0.2x in FY26, while gross interest coverage improved to 16.1x. [11]
That 0.2x is not directly comparable with the Q2 KPI figure of 2.19x because it is an agency-defined adjusted ratio for FY26. The rating release does not provide an adjusted net-leverage figure for 1HFY27; it reports 1HFY27 gross interest coverage of 18x instead. [24] Therefore, the Q2 KPI ratio should be read as evidence of balance-sheet leverage rising during the capex cycle, not as a direct revision of Ind-Ra’s FY26 adjusted ratio.
Does this represent a structural capex-funding shift?
It indicates a near-term change in the funding mix, but not yet a proven structural change in capital-allocation policy.
- Sai has planned FY27 capex of ₹1,100–1,300 Cr, of which approximately ₹620 Cr had been incurred in 1HFY27. Ind-Ra expects the programme to be funded through a combination of internal accruals and incremental borrowings. [11]
- The company had availed approximately ₹70 Cr of term debt by 1HFY27 and was expected to raise additional borrowings in 2HFY27. Scheduled repayments were expected to be funded through internal accruals. [25]
- Ind-Ra explicitly expects net leverage to rise from the current low base and free cash flow to remain constrained while the new capacity is commissioned and ramped up. [26]
- The rating remains stable because Ind-Ra expects the higher capex burden to remain manageable, supported by operating profitability, cash generation, available cash balances and liquidity headroom. [25]
The analytical reading is therefore “investment-phase leverage” rather than “permanent balance-sheet re-leveraging.” The rating action validates Sai’s ability to absorb a defined expansion programme; it does not establish a new long-term policy of financing future capex predominantly through debt. For capex beyond the FY27 programme, a separate funding framework could not be confirmed.
The key rating monitorable is whether capacity commissioning and utilisation lift EBITDA quickly enough to bring adjusted net leverage back below 1.5x. Ind-Ra identifies sustained leverage above that level, alongside weaker-than-expected EBITDA or higher debt, as a potential negative-rating trigger. [25]
| Company | Q2 FY27 Net Debt/EBITDA | TTM Q2 FY27 Net Debt/EBITDA | Relative position |
|---|---|---|---|
| Sai Life Sciences | 2.19x [12] | 0.57x [14] | High on Q2 snapshot |
| Emcure Pharmaceuticals | 2.25x [13] | 0.63x [15] | Highest in the set |
| Ipca Laboratories | 0.60x [16] | 0.17x [17] | Moderate |
| Ajanta Pharmaceuticals | 0.02x [18] | 0.01x [19] | Near net cash |
| GlaxoSmithKline Pharmaceuticals | -1.37x [20] | -0.41x [21] | Net cash |
| Acutaas Chemicals | -1.56x [22] | -0.44x [23] | Net cash |
Sources
- [1]India Ratings Upgrades Sai Life Sciences's Bank Loans to ' ... — Indiaratings, 2026-11-13T20:04:37.165578
- [2]Sai Life Science Earnings Call Transcript: Key Takeaways | SAILIFE | 6 Nov 2026 — Alfafinder, 2026-11-06T00:00:00
- [3]Total Debt
- [4]Total Debt
- [5]Total Debt YoY
- [6]TTM EBITDA
- [7]Is Sai Life Sciences a Good Buy? — Sovrenn, 2026-09-25T00:00:00
- [8]Total Debt
- [9]Sai Life Sciences Ltd. Bank Loan Credit Rating Upgraded to IND AA by India Ratings — 2026-11-13T21:45:39.727000, p.1
- [10]TTM Interest Coverage Ratio
- [11]Sai Life Sciences Ltd. Bank Loan Credit Rating Upgraded to IND AA by India Ratings — 2026-11-13T21:45:39.727000, p.3
- [12]Net Debt to EBITDA
- [13]Net Debt to EBITDA
- [14]TTM Net Debt to EBITDA
- [15]TTM Net Debt to EBITDA
- [16]Net Debt to EBITDA
- [17]TTM Net Debt to EBITDA
- [18]Net Debt to EBITDA
- [19]TTM Net Debt to EBITDA
- [20]Net Debt to EBITDA
- [21]TTM Net Debt to EBITDA
- [22]Net Debt to EBITDA
- [23]TTM Net Debt to EBITDA
- [24]Sai Life Sciences Ltd. Bank Loan Credit Rating Upgraded to IND AA by India Ratings — 2026-11-13T21:45:39.727000, p.5
- [25]Sai Life Sciences Ltd. Bank Loan Credit Rating Upgraded to IND AA by India Ratings — 2026-11-13T21:45:39.727000, p.4
- [26]Sai Life Sciences Ltd. Bank Loan Credit Rating Upgraded to IND AA by India Ratings — 2026-11-13T21:45:39.727000, p.2
Keep digging